Windward Bio
Updated: May 05, 2026
CEO - Luca Santarelli
Country: Switzerland | Funding: $200M (+)
Founded: 2024
Website: https://windwardbio.com/
Windward Bio develops long-acting bispecific antibodies, targeting validated biology in respiratory and dermatological conditions. It's lead candidate, a twice-yearly anti-TSLP agent dubbed WIN378 is undergoing clinical trial to treat asthma and chronic obstructive pulmonary disease. The pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLPxIL-13 bispecific with broad therapeutic potential across immunological diseases
Founded: 2024
Website: https://windwardbio.com/
Windward Bio develops long-acting bispecific antibodies, targeting validated biology in respiratory and dermatological conditions. It's lead candidate, a twice-yearly anti-TSLP agent dubbed WIN378 is undergoing clinical trial to treat asthma and chronic obstructive pulmonary disease. The pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLPxIL-13 bispecific with broad therapeutic potential across immunological diseases
